Published online Sep 27, 2023. doi: 10.4240/wjgs.v15.i9.2032
Peer-review started: June 8, 2023
First decision: July 7, 2023
Revised: July 13, 2023
Accepted: August 4, 2023
Article in press: August 4, 2023
Published online: September 27, 2023
Processing time: 106 Days and 11.6 Hours
Early detection of colorectal cancer (CRC) is essential to reduce cancer-related morbidity and mortality. Stool DNA (sDNA) testing is an emerging method for early CRC detection. Syndecan-2 (SDC2) methylation is a potential biomarker for the sDNA testing. Aberrant DNA methylation is an early epigenetic event during tumorigenesis and can occur in the normal colonic mucosa during aging, which can compromise the sDNA test results.
To determine whether methylated SDC2 in sDNA normalizes after surgical resection of CRC.
In this prospective study, we enrolled 151 patients with CRC who underwent curative surgical resection between September 2016 and May 2020. Preoperative stool samples were collected from 123 patients and postoperative samples were collected from 122 patients. A total of 104 samples were collected from both preoperative and postoperative patients. Aberrant promoter methylation of SDC2 in sDNA was assessed using linear target enrichment quantitative methylation-specific real-time polymerase chain reaction. Clinicopathological parameters were analyzed using the results of SDC2 methylation.
Detection rates of SDC2 methylation in the preoperative and postoperative stool samples were 88.6% and 19.7%, respectively. Large tumor size (3 cm, P = 0.019) and advanced T stage (T3–T4, P = 0.033) were positively associated with the detection rate of SDC2 methylation before surgery. Female sex was associated with false positives after surgery (P = 0.030). Cycle threshold (CT) values were significantly decreased postoperatively compared with preoperative values (P < 0.001). The postoperative negative conversion rate for preoperatively methylated SDC2 was 79.3% (73/92).
Our results suggested that the SDC2 methylation test for sDNA has acceptable sensitivity and specificity. However, small size and early T stage tumors are associated with a low detection rate of SDC2 methylation. As the cycle threshold values significantly decreased after surgery, SDC2 methylation test for sDNA might have a diagnostic value for CRC.
Core Tip: This prospective study evaluated the detection of syndecan-2 (SDC2) methylation in preoperative and postoperative stool DNA samples of colorectal cancer (CRC) patients. The study demonstrated that the SDC2 methylation test showed high sensitivity (88.6%) for detecting CRC before surgery, indicating its potential as a non-invasive diagnostic tool. Postoperatively, the detection rate decreased to 19.7%, suggesting the normalization of SDC2 methylation after surgical resection. The study highlights the diagnostic value of SDC2 methylation in preoperative and postoperative stool samples, supporting its role as a non-invasive screening tool for CRC.